Literature DB >> 9711108

[Radiofrequency ablation of multiple atrioventricular accessory pathways in a patient with syncope, atrial fibrillation and fasciculoventricular fibers].

M Valentino1, L Mont, L Aguinaga, I Anguera, I Eizmendi, J Sánchez, L Guillamón, M Matas, J Brugada.   

Abstract

Multiple accessory pathways in patients with the Wolff-Parkinson-White syndrome are infrequent and are associated with a higher risk of ventricular fibrillation. We present an exceptional case of a patient with four accessory pathways with anterograde conduction and a fasciculo-ventricular fiber in whom we performed a radiofrequency ablation. A 20 year old healthy male patient was seen at the emergency room after suffering syncope. The electrocardiogram showed atrial fibrillation with wide QRS complex suggestive of preexcitation. The electrophysiologic study demonstrated the presence of four atrio-ventricular accessory pathways with antegrade conduction (left lateral, right posteroseptal, right midseptal and right posterolateral). After ablation of the fourth accessory pathway, the electrocardiogram showed a persistent delta wave with a short HV interval. Atrial stimulation demonstrated decremental conduction, progressive lengthening of the AH interval and no modification in the HV interval nor in the preexcitation pattern, suggestive of the presence of a fasciculo-ventricular fiber. This exceptional case report is demonstrative of the complexity of the Wolff-Parkinson-White syndrome, and the feasibility and efficacy of radiofrequency catheter ablation in a single procedure.

Entities:  

Mesh:

Year:  1998        PMID: 9711108     DOI: 10.1016/s0300-8932(98)74793-1

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  1 in total

1.  Multiple Ablation Targets in Children: Multiple Accessory Pathways and Coexistent Arrhythmia.

Authors:  İlker Ertuğrul; Kutay Sel; Alper Akın; Hayrettin Hakan Aykan; Tevfik Karagöz
Journal:  Pediatr Cardiol       Date:  2021-07-09       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.